Effects and safety of Korodin Herz-Kreislauf-Tropfen on moderate hypotension and influence on cognitive functions in adults

Status

Not yet recruiting

Phases

Phase 1Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-003264-13-DE

Enrollment

120

Registered

2018-03-26

Start date

2018-04-13

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate low blood pressure

Interventions

Trade Name: Korodin® Herz-Kreislauf-Tropfen Pharmaceutical Form: Oral drops, liquid INN or Proposed INN: D-Camphor Other descriptive name: D-CAMPHOR Concentration unit: g gram(s) Concentration number

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: moderate low blood pressure Subjects must have moderate low blood pressure but be otherwise healthy as judged on the Basis of a medical examination Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: no low blood pressure other medications, alcohol if female: pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s): Change of moderate low blood pressure;Timepoint(s) of evaluation of this end point: Change of moderate low blood pressure before - meanwhile and after Trial - 1,3,7,15 minutes after oral intake	—

Secondary

Measure	Time frame
Secondary end point(s): Change of cognitive and mental functions;Timepoint(s) of evaluation of this end point: immediately after trial 15 and 30 minutes	—

Countries

Germany

Contacts

Public ContactRobugen GmbH

Robugen GmbH

mauzm@robugen.de004971113630111

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026